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infections caused by carbapenemase-producing, multidrug-resistant (MDR), or extensively drug-
resistant (XDR) Gram-negative bacteria constitute a major therapeutic challenge. Whether combination 
antibiotic therapy is superior to monotherapy remains unknown. in this systematic review and meta-
analysis oViD MeDLine, eMBASe, pubMed, the cochrane Library, and Scopus databases were 
searched for randomized controlled trials (Rcts) and observational studies published by December 
2016 comparing mono- with combination antibiotic therapy for infections with carbapenemase-
producing, MDR, or XDR Gram-negative bacteria. Mortality and clinical cure rates served as primary 
and secondary outcome measures, respectively. Of 8847 initially identified studies, 53 studies – 
covering pneumonia (n = 10 studies), blood stream (n = 15), osteoarticular (n = 1), and mixed infections 
(n = 27) - were included. 41% (n = 1848) of patients underwent monotherapy, and 59% (n = 2666) 
combination therapy. in case series/cohort studies (n = 45) mortality was lower with combination- vs. 
monotherapy (RR 0.83, CI 0.73–0.93, p = 0.002, I2 = 24%). Subgroup analysis revealed lower mortality 
with combination therapy with at least two in-vitro active antibiotics, in blood stream infections, 
and carbapenemase-producing Enterobacteriaceae. No mortality difference was seen in case-control 
studies (n = 6) and RCTs (n = 2). Cure rates did not differ regardless of study type. The two included RCTs 
had a high and unknown risk of bias, respectively. 16.7% (1/6) of case-control studies and 37.8% (17/45) 
of cases series/cohort studies were of good quality, whereas quality was poor in the remaining studies. 
in conclusion, combination antimicrobial therapy of multidrug-resistant Gram-negative bacteria 
appears to be superior to monotherapy with regard to mortality.
In an era of increasing antibiotic resistance rates, multidrug-resitant (MDR) Gram-negative bacteria constitute 
a major problem in the treatment of affected patients all over the world. The discovery void of new antibiotics, 
in particular antibiotics targeting Gram-negative bacteria, is further contributing to the problem and oftentimes 
necessitates the use of old drugs like polymyxins (colistin (polymyxin E) or polymyxin B), despite their well 
known and common serious side effects1. There is controversy on whether or not combination antimicrobial 
therapy is superior to monotherapy for infections with MDR pathogens. Many physicians prefer combination 
antimicrobial therapy over monotherapy, inferring superior outcomes mainly from in vitro experiments display-
ing synergistic effects of various antibiotics2. There are only few clinical studies comparing the effect of combi-
nation therapy versus monotherapy, most of them being retrospective cohort studies and case series limited by 
small study size. To account for the numerous confounding factors would require cohort studies including several 
hundreds to thousands of patients3. Furthermore, well-powered randomized controlled trials (RCTs) are lacking.
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We conducted a systematic review and meta-analysis to investigate the effect of combination antimicrobial 
therapy versus monotherapy against multi-resistant Gram-negative bacteria on mortality as a primary outcome 
and cure rate as secondary outcome.
Methods
Data sources and searches. For this systematic review and meta-analysis, an electronic search of OVID 
MEDLINE, EMBASE, Scopus, The Cochrane Central Register of Controlled Trials (CENTRAL), and PubMed was 
performed with the help of a librarian with expertise in literature search for systematic reviews and meta-analyses. 
Studies published by December 2016 were included. For a detailed search strategy see Supplementary Materials 
(Supplementary Table 1).
Study selection. RCTs, case-control studies, cohort studies and case series comparing outcomes of antibiotic 
monotherapy versus combination therapy of infections caused by carbapenemase-producing, MDR, XDR and 
PDR Gram-negative bacteria were included. We retained the definition of MDR and XDR used by respective 
study authors. Studies including not only carbapenemase-producing, MDR, XDR or PDR Gram-negative bacte-
ria were excluded unless outcome data of infections caused by carbapenemase-producing, MDR, XDR or PDR 
bacteria were reported separately. Moreover, studies with inclusion of bacteria with resistance mechanisms to 
carbapenems other than carbapenemase production, studies reporting on patients under the age of 16 years, case 
series lacking a comparison group or including fewer than ten patients were excluded. No restriction by study site, 
country, follow-up period, dose, or frequency of drug application was applied. Only studies addressing parenteral 
and oral drug administration were included; antibiotics that got applied by inhalation or topically were not con-
sidered. Only studies published in English were considered eligible.
Titles and abstracts were screened and inclusion criteria applied by one author (AS). Full text articles of poten-
tially relevant publications were obtained and reviewed independently by two out of three authors (AS, AW, SK) 
who took the decision on final inclusion by consensus. In case no agreement could be reached, the third author 
was consulted and final unanimous decision was taken after an in-depth discussion.
Data extraction and quality assessment. Data extraction from included trials was performed by two of 
three authors (AS, AW, SK) using a standardized data collection form. In case of missing data, no attemps were 
made to contact study authors. Following data were extracted from studies: study design, microorganism and 
type of resistance, disease, antibiotics used in mono- and combination therapy and outcome measures. All-cause 
mortality and clinical cure rates, as defined in the individual studies, served as primary and secondary outcome 
measures, respectively. If the endpoints mortality or cure was only reported as probability, data were extracted as 
proportions.
In the monotherapy group, only patients treated with a single antibiotic drug were included, whereas in the 
combination therapy group patients treated with two or more antibiotics given simultaneously were included – 
regardless of in vitro susceptibility. Beta-lactamase inhibitors (i.e. sulbactam, clavulanic acid) were not considered 
independent antibiotic substances.
Quality assessment of RCTs with regard to method and risk of bias included: sequence generation, alloca-
tion concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. 
Definitions/criteria were derived from the Cochrane Handbook for Systematic Reviews of Interventions4. 
Quality assessment and risk of bias of case-control studies comprised following criteria: selection, comparability, 
and exposure, according to the Newcastle-Ottawa quality assessment scale for case-control studies5. To assess 
quality and risk of bias of cohort studies, selection, comparability, and outcome was accounted for, using the 
Newcastle-Ottawa quality assessment scale for cohort studies5. Thresholds for converting the Newcastle-Ottawa 
scales to Agency for Healthcare Research and Quality (AHRQ) standards (good, fair and poor) were as follows: 
good quality if three or four stars in selection domain and one or two stars in comparability domain and two or 
three stars in outcome/exposure domain. Fair quality if two stars in selection domain and one or two stars in com-
parability domain and two or three stars in outcome/exposure domain. Poor quality if zero or one star in selection 
domain or zero stars in comparability domain or zero or one star in outcome/exposure domain6.
Data synthesis and analysis. For Data synthesis and analysis, Review Manager (Version 5.3, The Cochrane 
Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) was used. Due to anticipated heterogeneity 
between studies, random effects models were used for all analyses to obtain a summary estimate (risk ratio (RR)) 
of the average effect with its 95% confidence interval (CI). P-values ≤ 0.05 were considered statistically significant. 
Subgroup analyses for various resistance mechanisms, disease entities, antibiotics and quality of studies were per-
formed. Statistical heterogeneity was initially inspected graphically using forest plots. The degree of heterogeneity 
was quantified by using the I2 statistic with a threshold of I2 > 60% for high heterogeneity. Publication bias was 
investigated using a funnel plot in which the standard error of the effect estimate of each study was plotted against 
the estimate.
Results
Study selection. Figure 1 shows the study selection process according to the Preferred Reporting Items 
for Systematic reviews and Meta-Analyses for Protocols (PRISMA). The initial search yielded 8847 references. 
After screening titles and abstracts and exclusion of duplicates, 182 articles were selected for full-text screening, 
after which 53 studies were retained for the analysis. Included studies are depicted in Supplementary Table 2. 
Addressed infections ranged from pneumonia (n = 10 studies)7–16, blood stream infections (n = 15 studies)17–31, 
osteoarticular infections (n = 1 study)32, and studies comprising mixed forms of infections (n = 27 studies)33–59. 
Two of the included studies were RCTs36,43, six case-control studies7,9,15,17,53,55 and forty-five case series/cohort 
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studies8,10–14,16,18–35,37–42,44–52,54,56–59. The studies included a total of 4514 patients: 41% of patients (n = 1848) were 
treated with monotherapy, 59% (n = 2666) with combination therapy.
Monotherapies comprised colistin, polymyxin B, minocycline, doxyxycline, carbapenem, tigecycline, 
beta-lactam/beta-lactamase inhibitor, cephalosporin, aminoglycoside, fosfomycin, nitrofurantoin, and fluoro-
quinolone. Combination therapy comprised colistin-based combinations, polymyxin B-based combinations, 
minocycline-based combinations, carbapenem-based combinations, tigecyclin-based combinations, and various 
other combinations. The following resistant bacteria were addressed by the studies: MDR Pseudomonas aerug-
inosa, Metallo-Beta-lactamase-producing Pseudomonas aeruginosa, MDR/XDR and pan-drug resistant (PDR) 
Acinetobacter baumanii, carbapenemase-producing Enterobacteriaceae (incl. KPC), and mixed MDR/XDR 
Gram-negatives.
Mortality. All studies reporting on mortality totalled 2105 patients (56.3%) with combination therapy and 
1633 patients (43.7%) with monotherapy.
case series and cohort studies. Meta-analysis of all case series and cohort studies included 1813 patients 
(56.7%) with combination therapy and 1383 patients (43.3%) with monotherapy and demonstrated a lower mor-
tality risk in the combination therapy group (RR: 0.83, 95% CI 0.73–0.93, p = 0.002). Heterogeneity was low 
(I2 = 24%, p = 0.1).
Subgroup analysis of various bacteria and resistance mechanisms indicated a superior outcome of com-
bination therapy versus monotherapy in the treatment of infections caused by carbapenemase-producing 
Enterobacteriaceae (RR 0.74, 95% CI 0.59–0.93, p = 0.01; I2 = 26%, p = 0.17). In infections caused by other resist-
ant bacteria, i.e. MDR Pseudomonas aeruginosa, Metallo-Beta-lactamase-producing Pseudomonas aeruginosa, 
MDR/XDR Acinetobacter baumanii and mixed MDR/XDR Gram negative bacteria, no difference in mortality 
was detected (Fig. 2).
Subgroup analysis of various diseases revealed an advantage of combination therapy when applied in blood-
stream infections (RR 0.78, 95% CI 0.63–0.96; p = 0.02; I2 = 27%, p = 0.17), whereas no difference could be seen 
in pneumonia or studies including mixed forms of infections. In studies that only included bloodstream infec-
tions (n = 14), stratified according to bacteria and resistance mechanism, combination therapy was superior in 
the group of carbapenemase-producing Enterobacteriaceae (RR: 0.61, CI 95% 0.45–0.85, p = 0.003; I2 = 21%, 
p = 0.26), with no difference in MDR/XDR Acinetobacter baumanii and mixed MDR/XDR Gram-negative bac-
teria (Supplementary Fig. 1). Subgroup analysis including only infections due to carbapenemase-producing 
Enterobacteriaceae, stratified by different disease types, again showed lower mortality rates in bloodstream infec-
tions (RR 0.61, CI 0.45–0.85, p = 0.003; I2 = 21%, p = 0.26) with no difference in the non-bloodstream infection 
group (comprising studies with mixed forms of infections) (Supplementary Fig. 2).
Subgroup analysis of different treatment strategies did not reveal a distinct combination therapy with a supe-
rior outcome compared to monotherapy. Analysis of the 12 studies with combination therapies that contained 
only one in-vitro active substance did not result in better outcomes against monotherapy, nor did subgroup anal-
yses stratified according to bacteria and diseases. Polymyxin combinations performed better than polymyxin 
monotherapy (n = 1; RR 0.63, CI 95% 0.41–0.96, p = 0.03). Colistin combinations performed better than mono-
therapies with various antibiotics (n = 1; RR 0.38, CI 0.22–0.65, p = 0.0005).
Meta-analysis of studies with combination therapy including at least two in vitro active substances (n = 24) 
showed lower mortality with combination therapy versus monotherapy (RR 0.82, CI 0.73–0.93, p = 0.002, 
Figure 1. Study selection.
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I2 = 3%, p = 0.41) (Fig. 3). Subgroup analysis in this group revealed better results with carbapenemase-producing 
Enterobacteriaceae (RR 0.73, CI 0.59–0.90, p = 0.003; I2 = 15%, p = 0.29) and bloodstream infections (RR 0.70, 
CI 0.53–0.91, p = 0.009; I2 = 25%, p = 0.22).
Subgroup analysis of good and poor quality studies revealed a significant lower mortality risk with combi-
nation antibiotic therapy versus monotherapy in good quality studies (RR: 0.78, 95% CI 0.69–0.88, p = 0.0001, 
I2 = 4%, p = 0.4). Among studies with poor quality, no difference in mortality in the combination therapy vs. 
the monotherapy group was detected. With regard to the different diseases, a significant difference of combi-
nation antibiotic therapy was seen in good quality studies of blood stream infections (RR: 0.75, 95% CI 0.61–
0.93, p = 0.009, I2 = 17%, p = 0.3) and good quality studies of mixed infections (RR: 0.77, 95% CI 0.64–0.92, 
p = 0.004, I2 = 5%, p = 0.38), whereas no advantage of combination therapy could be shown in poor quality 
studies. Subgroup analysis of different bacteria and quality of studies revealed a significant lower mortality with 
Figure 2. Risk ratios for mortality rates of case series and cohort studies stratified by different bacteria. Data 
markers indicate Risk ratios and error bars indicate 95% CIs.
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combination therapy of carbapenemase-producing Enterobacteriaceae in good quality studies (RR: 0.71, 95% CI 
0.60–0.84, p < 0.0001, I2 = 0%, p = 0.49) in contrast to poor quality studies.
case-control studies. Meta-analysis of case-control studies comprising 142 patients (50.4%) with com-
bination therapy and 140 patients (49.6%) with monotherapy did not show a significant difference in mortality 
between combination therapy and monotherapy. Neither did subgroup analyses of case-control studies compar-
ing different bacteria/resistance mechanisms, diseases and treatments show a difference in mortality between the 
two groups. In all included case-control studies, either only one in vitro active substance was used in the combi-
nation group or it was not clearly stated whether there were several in-vitro active substances in the combination 
group.
Figure 3. Risk ratios for mortality rates of case series and cohort studies stratified by different bacteria. 
Combination therapy with at least two in vitro active substances. Data markers indicate RRs and error bars 
indicate 95% CIs.
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The only study of good quality revealed a lower mortality of combination therapy (RR: 0.22, 95% CI 0.09–0.56, 
p = 0.001). Poor quality studies did not show any difference between combination therapy and monotherapy.
Randomized controlled trials. Meta-analysis of the two RCTs (150 patients with combination treatment, 
110 patients with monotherapy) and various subgroup analyses did not show a beneficial effect of combination 
therapy over monotherapy. In the combination groups of the included RCTs, two or more in-vitro active sub-
stances were used.
clinical cure rates. For meta-analysis of clinical cure rates, data from 1666 patients were available including 
case series, cohort and case-control studies. Among these, 1069 patients (64.2%) received combination therapy 
and 597 patients (35.8%) were treated with a monotherapy.
case series and cohort studies. Meta-analysis of case series and cohort studies with a total of 958 patients 
(67.0%) with combination therapy and 472 patients (33.0%) with monotherapy, did not show a difference in clin-
ical cure rates between mono- and combination therapy (Fig. 4).
Subgroup analysis of different bacteria, resistance mechanisms and quality of studies did not reveal a difference 
between mono- and combination therapy. A trend to higher cure rates in combination therapy was seen in MDR 
Pseudomonas aeruginosa, MDR Acinetobacter baumanii and carbapenemase-producing Enterobacteriaceae.
Subgroup analysis of different diseases revealed a difference between mono- and combination therapy in oste-
oarticular infection (n = 1; RR 0.43, CI 0.21–0.89, p = 0.02) but no difference in other types of infections (pneu-
monia, bloodstream infections, mixed forms of infection).
No difference in cure rates was seen with different antibiotic therapies, regardless of the number of substances 
with in-vitro activity in combination treatment groups (Fig. 5).
case-control studies. Meta-analysis of case-control studies, including 125 patients (53.0%) with mono- and 
111 patients (47.0%) with combination therapy, did not show any difference of monotherapy vs. combination 
therapy with regard to clinical cure rates. Subgroup analyses looking at different bacteria/resistance mechanisms, 
diseases (pneumonia, mixed) and treatments did not show any difference in clinical cure rates.
Figure 4. Risk ratios for clinical cure rates of case series and cohort studies stratified by different bacteria. Data 
markers indicate Risk ratios and error bars indicate 95% CIs.
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Study quality. The quality of included studies was variable. Two of the included studies were RCTs, one of 
which was un-blinded and the other one did not report on blinding leading to potential performance bias. One 
RCT showed an overall high risk of bias and the second one an overall unknown risk of bias (Supplementary 
Table 3). Only one out of six included case-control studies (16.7%) and 17 out of 45 (37.8%) included cases series 
and cohort studies showed an overall good quality with good comparability of cases and controls. The remaining 
studies were prone to confounding factors resulting in poor quality (Supplementary Table 4 and Supplementary 
Table 5). Funnel plots did not suggest publication bias (data not shown).
Discussion
In this large meta-analysis including 53 studies with a total of 4514 patients, overall mortality in case series and 
cohort studies was lower in patients treated with antibiotic combination therapy. Specifically, lower mortality rates 
were detected in patients with bloodstream infections and in infections caused by carbapenemase-producing 
Enterobacteriacae if combination therapy entailed at least two substances with in-vitro activity. There was no 
difference in mortality rates if combination therapy comprised only one in-vitro active substance, in RCTs (2 
studies; several in-vitro active substances in combination therapy) and case-control studies (5 studies; only one 
in-vitro active substance in combination therapy). These effects were confirmed when restricting our analyses to 
studies of good quality.
Eight19,20,24,25,27,29,31 out of fourteen case series and cohort studies (57%) that included patients with blood-
stream infections were due to carbapenemase-producing Enterobacteriaceae. These studies also accounted for 
53% (8/15) of all included case series and cohort studies due to carbapenemase-producing Enterobacteriaceae. 
The mortality rate of patients with bloodstream infections with bacteria other than carbapenemase-producing 
Enterobacteriaceae did not differ between combination and monotherapy. Likewise, non-bloodstream infections 
by carbapenemase-producing Enterobacteriaceae did not show a superior effect of combination therapy. Thus, 
it is likely that the superior effect of combination therapy with infections caused by carbapenemase-producing 
Enterobacteriaceae and with bloodstream infections is actually one and the same.
Our results are in line with published results by Zusman et al.60, who showed lower mortality with polymyxin/
carbapenem or polymyxin/tigecycline, aminoglycosides or fosfomycin combination therapy compared to poly-
myxin monotherapy in carbapenem-resistant bacteria and could also show a benefit of combined treatment in 
bloodstream infections. In contrast to our meta-analysis, Zusman et al. included carbapenem-resistant bacteria 
in general (i.e. also including carbapenem resistance due to porin loss), and regarded betalactamase inhibitors 
(i.e. sulbactam) as separate antibiotic substances. Furthermore, Zusman et al. only included carbapenem-resistant 
bacteria and only polymyxin mono- and combination therapy, whereas our analysis comprised different multire-
sistant bacteria and antimicrobials.
In theory, several facts argue against the application of combination therapy: the possible rise in resistance 
rates due to an overall increase in selection pressure as a result of a greater release of antibiotics into the environ-
ment61, higher rates of adverse effects (such as nephro- and ototoxicity due to colistin or aminoglycosides)61, an 
increase in Clostridium difficile-associated infections, fungal infections3, higher costs61, and possible antagonism3. 
On the other hand, several factors argue in favour of combination therapy: a broader antibiotic spectrum, in vitro 
data showing synergy of antibiotic combinations2, lower efficacy of colistin monotherapy compared to betalactam 
Figure 5. Risk ratios for clinical cure rates of case series and cohort studies stratified by different bacteria. 
Combination therapy with at least two in vitro active substances. Data markers indicate Risk ratios and error 
bars indicate 95% CIs.
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monotherapy62, lower risk of resistance development (e.g. against colistin)1, lower doses and shorter treatment 
duration61.
Observational study designs are prone to several limitations, mainly due to unmeasured confounding factors 
and other risks of bias. The likelihood of inappropriate empirical antibiotic therapy is higher in the monotherapy 
group and the time to start of appropriate monotherapy after results from susceptibilty testing are known may 
be longer compared to the combination therapy group, which may result in a bias in favour of combination ther-
apy3. Information about the dosing of colistin was only reported in a minority of the included studies12,27,29,34. 
As guidance has changed in recent years and a loading dose is now generally recommended, colistin could have 
been underdosed in a significant proportion of studies, which may constitute a bias against colistin monother-
apy3. Furthermore, there is a chance of selection bias in favour of combination therapy, as patients are more 
likely to receive colistin or tigecyclin monotherapy if bacteria are resistant to all other antibiotics as compared 
to situations where bacteria are still susceptible to carbapenems, for example, or in patients who suffer from 
polymicrobial infections with resistant as well as susceptible strains3. Such an effect could result in a perceived 
lower overall mortality in the combination treatment group at least partly due to a subgroup of carbapenem 
susceptible Gram-negative bacteria20,29,56. Moreover, combination therapy is more likely prescribed to patients 
with polymicrobial infections in which one does not know for sure whether the resistant bacterium is the main 
causative agent3. Against the latter argues the fact that an advantage of combination therapy could be shown in 
bloodstream infections, where one can almost be certain of the main causative agent, in analogy to Zusman and 
colleagues60. Finally, one could argue that combination therapy is more likely to be prescribed in more serious 
infections, which would bias the results in favour of monotherapy.
Due to numerous limitations and biases, which is reflected in the quality assessment of included studies, 
the results of this metaanalysis have to be interpreted with caution. However, by inclusion of a wide variety of 
cohort studies and case series, including a heterogeneous group of infectious diseases, bacteria, and treatments, 
we tried to minimize existing biases and limitations and allow for a valid comparison of combination treatment 
with monotherapy. Moreover, the favourable effect of combination therapy in bloodstream infections due to 
carbapenmase-producing Enterobacteriaceae has recently been confirmed in a large retrospective cohort for the 
subset of patients with severe infections63. With regard to RCTs and case-control studies, the validity of the results 
of our meta-analysis of RCTs and case-control studies is very limited due to the low number and limited power 
of the included studies.
To reach a final conclusion as to the possible advantage of combination therapy versus monotherapy, well 
designed and sufficiently powered RCTs are needed. Two RCT’s currently being undertaken could bring some 
more clarity in this contentious issue64,65. Such trials, however, will always have the problem to be prone to the 
conclusion that their findings can only be applied to the population under study. Only pragmatic trial designs 
will help resolve this issue. For the time being and taking into account limiting factors of RCTs, such as problems 
in reaching sufficient power in the setting of uncommon diseases as well as costs, other forms of study (cohort 
studies, case series, case-control studies) provide valid and valuable data on the best evidence-based treatment66. 
Individual patient-data meta-analyses may add further insights when it proves to be difficult to obtain large 
enough sample sizes for certain study questions.
Based on our results, combination therapy with two antimicrobials that demonstrate in vitro activity should 
be administered in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae.
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